Persson F, et al. – The present study sought to compare the sodium glucose–cotransporter–2–inhibitor (SGLT–2i) dapagliflozin versus dipeptidyl peptidase–4 inhibitors (DPP–4i) regarding risk associations of MACE (nonfatal myocardial infarction, nonfatal stroke or cardiovascular [CV] mortality), hospital events for heart failure (HHF), atrial fibrillation, and severe hypoglycemia for type 2 diabetes (T2D) patients in a real–world setting. The study results showed that dapagliflozin was related to lower risks of cardiovascular events and all–cause mortality compared to DPP–4i in a real–world clinical setting and broad T2D population.